Access to Healthcare
Adhering to the mission of “For the health, For the future”, we focus on the healthcare industry and has been endeavouring to improve the availability and affordability of medicines and advocate for the rational use of drugs. Moreover, we actively fulfil our obligations & duties in the popularity of medical products domestically and abroad.
Management System of Access to Healthcare
The Social Responsibility Committee of the Board of Directors of Joincare has considered Access to Healthcare issues during its decision-making. It is responsible for regularly reviewing the development of the Group's strategies & policies and performance on Access to Healthcare, supervising and reporting the progress to the Board of Directors, and urging the Group to practice Access to Healthcare issues.
Improving Products’ Availability
To improve our products’ availability and make more safe and effective products available to global patients, Joincare expands the production and marketing of vaccines, patent medicines, generics, APIs, and IVD (In-Vitro Diagnostics) reagents and devices overseas mainly via direct operation and authorising local distributors. So far, our products have been approved for registration in major pharmaceutical markets and emerging markets in multiple countries and areas across Asia, Europe, North America and Africa.
During 2022, our revenues generated from overseas businesses reached RMB2,841.96 million, representing a 5-year compound growth rate of 12.67%.
Case: Process of Joincare’s Internationalisation
Internationalisation is the long-term strategy of Joincare’s development. In 2022, we launched the Global Depository Receipt (GDR) in Switzerland successfully, which is a major milestone in the internationalisation process of the Group. The speed of internationalisation of the Group will be further increased by launching the GDR. Also, we proceed with the work of admittance, product registration, and promotion for products such as inhalation formulation, assisted reproduction, gastroenterology, and anti-viral overseas. Ilaprazole Sodium for Injection and Ilaprazole Enteric-Coated Tablets, which are our major products, are granted for sale in the Indonesian market. We are conducting registration-related work for Recombinant Human Choriogonadotropin alfa for Injection; registration materials were submitted to Indonesia, Pakistan, five countries in Central and South America and two countries in Central Asia; the product is granted for sale in Tajikistan. Products such as Budesonide Suspension for Inhalation and Compound Ipratropium Bromide Solution for Inhalation are being registered in countries like the Philippines. Budesonide Suspension for Inhalation is registered in Macao, and the first overseas sale is completed.
Meanwhile, we promote international cooperation and external licensing and authorisation of innovative products and pipelines, and we conduct discussions on cooperation with international multi-parties. Among them, we are discussing external authorisation of the modified new drugs Tobramycin Inhalation Solution with customers in European and Southeast Asia.
2,841.96 million(RMB)
Revenue generated from overseas businesses of the Group during 2022
12.67%
5-year compound growth rate
Improving Medical Affordability
To improve the affordability of medicines, the Group actively responds to admission to the medical insurance list, making efforts to provide high-quality medicines to more patients at affordable prices. In addition, Joincare has been keeping track of the national centralised drug procurement, striving to be included in the national procurement list, providing fairly-priced and high-quality medicines to patients in the future.
In terms of product pricing, when entering into overseas markets, Joincare comprehensively considers the local economy, healthcare level, and price benchmarking to offer equitable pricing in line with the current regional development, avoiding an increase in the financial burden of patients. After an adequate assessment of local per capita income and analysis of local patients' affordability, differential-tiered pricing strategies were implemented for different markets. Joincare also positively goes for the bidding of local governments during product promotion in developing countries overseas so that affordable medicines and services would be offered locally. By the end of 2022, the Group and its subsidiaries have adopted equitable pricing policies in selling of 25 products in South Asia, Southeastern Asia, South America and Africa to match the local income level.
In 2022, in the new version of the National Medicine List for Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (NRDL) published by the National Healthcare Security Administration, Joincare had 202 products included, among which 95 were Class A and 107 were Class B.
In 2022, two products of Joincare won the bid for the seventh batch of national procurement.
202 products
Included in the NRDL
95 products
On the NRDL Class A list
107 products
On the NRDL Class B list
2 products
Won the bid for the seventh batch of national procurement
Access to Public Welfare for Chronic Diseases Prevention and Treatment Program
Acting upon the national policy of rural revitalisation and common prosperity, Joincare helps consolidate and expand the achievements made in poverty alleviation in coordination with the extensive drive for rural revitalisation. In particular, Joincare, by leveraging its industrial advantages, joined hands with the Group’s holding subsidiary Livzon Group to carry on the “Access to Public Welfare for Chronic Diseases Prevention and Treatment Program”. We donated drugs for treating chronic diseases, including Pravastatin Capsules (普伐他汀钠胶囊), Amlodipine Besylate Capsules (苯磺酸氨氯地平胶囊), Valsartan Capsules (缬沙坦胶囊) and Isosorbide Mononitrate Tablets (单硝酸异山梨酯片) to poor families in remote areas with chronic diseases, such as hypertension, hyperlipidemia, cardio-cerebral diseases. In doing so, we expected to reduce the medical burden of patients’ families. Since late 2018 onwards, we have carried out the “Access to Public Welfare for Chronic Diseases Prevention and Treatment Program” successively in areas including Sichuan Province, Shanxi Province, Gansu Province, Jilin Province, Tibet Autonomous Region, Henan Province, Anhui Province, Hunan Province, Jiangxi Province as part of our efforts to promote rural health. In 2022, this program was honoured as the “Top 100 Citizen Satisfaction Projects” in the 19th session of Shenzhen Project Care.
By the end of 2022, we had signed 19 agreements on the “Access to Public Welfare for Chronic Diseases Prevention and Treatment Program”, which covers 8 provinces and 1 autonomous region, including 17 remote areas in need of help, and benefiting over 6,400 patients on low income and with chronic diseases.
19
Agreements on the “Access to Public Welfare for Chronic Diseases Prevention and Treatment Program” have been signed
17
Remote areas in need of help
9 areas
Covers 8 provinces and 1 autonomous region
6,400 +
Patients on low income and with chronic diseases have benefited from the program
Popularising Knowledge of Chronic
Disease Respiratory disease is China's third most common chronic disease after cardiovascular disease and diabetes, with more than 160 million patients. To increase public awareness of chronic respiratory diseases, with measures such as publishing academic papers, supporting academic research, holding and participating in offline academic promotion activities, and organising online live-broadcasting via new media, Joincare endeavours in many ways to educate the public about asthma, COPD and other chronic respiratory diseases and encourages people potentially suffering from these diseases to take regular pulmonary function tests, to help prevent and treat chronic respiratory diseases.
“Respiratory Experts’ Views” has gathered more than 5,000 respiratory experts, aiming to build a top domestic alliance of pneumology departments, voice for disease science, and contribute to patient education.
5000 +
Respiratory Experts
“Respiratory Experts’ Views” has broadcast more than 100 live science popularization of respiratory diseases recorded by more than 200 experts, and has attracted more than 5 million live viewers and more than 3 million followers.
Case: “Respiratory Experts’ Views” public welfare activities
Joincare focuses on respiratory diseases. We build a popular science new media platform matrix called “Respiratory Experts’ Views”. Through new media channels such as WeChat official account, Douyin, and Weibo, we promote knowledge on chronic respiratory disease and give treatment support.
During the “World Asthma Day” activity in 2022, the “Respiratory Experts’ Views” platform initiated the activity themed “A small red envelope for you”. It simultaneously launched the live broadcasting of asthma knowledge for a week. During the activity, respiratory experts from 116 domestic hospitals were specially invited to spread the knowledge of asthma prevention and treatment to the public, jointly protecting respiratory health.
During the “World COPD Day” activity in 2022, the COPD activity themed “Identifying potential patients, 1/14 of the total” was initiated to invite the public to participate in the vital capacity self-test game “One Breath Challenge”. Moreover, the “2022 Live-broadcasting Week of COPD Knowledge” activity was held together with chief respiratory physicians from many grade-A tertiary hospitals, calling on the public to keep a healthy lung and promote early prevention and effective intervention for better treatment effect.
100 +
Live science popularization of respiratory diseases
200 +
Experts participated in the Recording
5 Million+
Live viewers
3 Million+
Followers
Eliminating the Indiscrimination Use of Antibiotics
Joincare holds that antibiotic resistance has become a global public health risk, threatening human health. As for R&D, we focus on medicine-resistance risk control for Tobramycin Inhalation Solution. Meanwhile, our holding subsidiary Livzon Pharmaceutical Group also keeps on conducting R&D to address antibiotic resistance, including drug resistance of Gram-Negative Bacteria and Fungi and works with stakeholders to develop solutions to antibiotic resistance. Joincare also takes an active part in a number of academic conferences and has in-depth exchanges with clinical experts in infection, respiratory, blood, ICU, organ transplantation, skin, obstetrics, and gynaecology and scholars engaged in basic research of microbiology. Through these efforts, we aim to promote development and innovation in the field of medicine to ensure that all people can live a healthy life.
Case: Medicine-resistance risk control for Tobramycin Inhalation Solution
Bronchiectasis, one of common chronic respiratory diseases in China, can be aggravated by pseudomonas aeruginosa. The frequent and acute attack of bronchiectasis due to the bacterium will increase the risk of hospitalisation. Studies have shown that pseudomonas aeruginosa is generally resistant to existing antibiotics. Though the bacterium is less resistant to Tobramycin, the systemic administration will exert greater side effects. Compared with the systemic administration, inhaled antibiotics, due to rapid topical aggregation, can avoid the first-pass effect, and reduce systemic adverse reactions and the medicine-resistance risk resulted from prolonged antibiotics therapy. During the R&D of Tobramycin Inhalation Solution, Joincare carried out the first phase III clinical study on the treatment of bronchiectasis accompanied with pseudomonas aeruginosa infection in China. Moreover, we are the first in the world to set the dual study endpoint of bacterial load and patient life quality, in which major study endpoint received double positive and significant curative effect summary. In addition to the obvious clinical efficacy, the blood concentration following nebulised inhalation of Tobramycin was at an absolutely safe level without ototoxicity, nephrotoxicity, or increasing medicine-resistance risk. The successful marketing of the product has provided a better option for China’s patients with bronchiectasis.
Enhancement of Healthcare Capacity
Joincare actively promotes cooperation with developing countries, and works with domestic and overseas pharmaceutical peers and healthcare workers to benefit patients around the world with innovative achievement and increase public health in developing countries. In addition, as an APIs supplier, Joincare shares its research results with less developed countries and regions overseas and proceeds technology transfer, and helps local pharmaceutical enterprises to improve and optimise production procedures and quality control routine by providing technology transfer and analysis and detection scheme. Therefore, the level of local production technology is increased.
Paying Attention to Rare Diseases Treatment
Rare diseases, also known as “orphan diseases”, are featured by unknown causes and extremely low incidence rates. High treatment costs for rare diseases result from their low market demand, difficulties in R&D and lack of experience in clinical medication, and even there is high cost and no medicine for some rare diseases. We based on our own scientific platform and capabilities, undertake corporate social responsibility actively by continuously investing in research on rare diseases, and focusing on improving the current situation of diagnosis and treatment of rare diseases, thus making contributions to building a Healthy China.
Scope of sales and R&D in Treatment for Rare Diseases
Rare diseases, also known as “orphan diseases”, are featured by unknown causes and extremely low incidence rates. High treatment costs for rare diseases result from their low market demand, difficulties in R&D and lack of experience in clinical medication, and even there is high cost and no medicine for some rare diseases. Under the guidance of relevant policies such as the “Healthy China 2030” Planning Outline and the Guidelines for Diagnosis and Treatment of Rare Diseases, we, based on our own scientific platform and capabilities, undertake corporate social responsibility actively by continuously investing in research on rare diseases, and focusing on improving the current situation of diagnosis and treatment of rare diseases, thus making contributions to building a Healthy China.
By the end of 2022, Joincare has sold products and has conducted ongoing R&D in 4 orphan disease areas.
Quick Navigation
Service Hotline
Quick
Navigation
Service
Hotline
Official WeChat Official Account
Copyright © Joincare Pharmaceutical Group Industry Co., Ltd. All Rights Reserved. Powered by:www.300.cn Zhuhai 粤ICP备14024104号